Investor Overview
Oncolytics Biotech, Inc.
Oncolytics is focused on obtaining regulatory approval for pelareorep for metastatic breast cancer and pancreatic cancer, indications with continued and considerable unmet needs. Based on very compelling data, Oncolytics believes that advancing pelareorep through late-stage clinical testing, submission and registration in these indications present the highest chance of success with the greatest commercial opportunity.
Press Releases
December 3, 2024
November 12, 2024
Events
November 12, 2024
September 11, 2024 ET
September 19, 2024 ET